Expression and clinicopathological features of human epidermal growth factor receptor 2-low local-ized high-risk and oligometastatic prostate adenocarcinoma
Objective The aim of this study was to investigate the expression characteristics of hu-man epidermal growth factor receptor 2-Low(Her-2-Low)in limited high-risk and oligometastatic prostate adenocarcinomas.The findings will provide data to support the application of Her-2-targeted agents.Methods A total of 100 patients who underwent robotic-assisted radical prostatectomy at the Department of Urology,People's Liberation Army(PLA)General Hospital from August 2021 to April 2023 were retro-spectively analysed and divided into the Androgen Deprivation Therapy(ADT)group(n=17)and non-ADT group(n=83)according to preoperative treatment or not,and into the localized high-risk group(n=71)and the oligometastatic group(n=29)according to metastatic status.The results of their Her-2 immu-nohistochemical staining were statistically analysed,Differences in measures were compared using the rank sum test,and differences in expression rates were compared using the chi-square test.Results Her-2-Low was expressed in approximately 59％of localized high-risk and oligometastatic prostate adenocarcinomas and no immunohistochemical 3+results were found;The rate of Her-2-Low expression was significantly higher in the ADT-treated group compared to the non-ADT-treated group[82.4％(14/17)vs.54.2％(45/83),x2=4.618,P＜0.05].Additionally,the oligometastatic group had a significantly higher rate of expression compared to the limited high-risk group[75.9％(22/29)vs.52.1％(37/71),x=4.801,P＜0.05].Conclusion Her-2-Low has a high expression rate in localized high-risk and oligometastatic prostate adenocarcinoma.There may be a higher proportion of trastuzumab-deruxtecan-sensitive patients in the group of patients with preoperative endocrine therapy and oligometastases.
NETL
NSTL
万方数据
